Leadership - Insphero

InSphero’s leadership team combines many years’ scientific and commercial experience in 3D microtissue engineering, cell based assays, laboratory automation, and industry-scale production and quality assurance. It is complemented by the strategic management expertise of our Board of Directors and Strategic Advisory Board members.

Management Team

Jan Lichtenberg, PhD
Jan Lichtenberg, PhD
Chief Executive Officer, Co-Founder
 
Wolfgang Moritz, PhD
Wolfgang Moritz, PhD
Head of External Collaborations & IP
 
Oliver Krähenbühl, MBA
Oliver Krähenbühl, MBA
Chief Financial Officer
 
Patrick Guye, PhD
Patrick Guye, PhD
Chief Scientific Officer
 
Frank Junker, PhD, MBA
Frank Junker, PhD, MBA
Chief Business Officer
 
Randy Strube, PhD
Randy Strube, PhD
Director of Global Marketing
 
Marion Bavand, PhD
Marion Bavand, PhD
Head of Quality Assurance 
 
Katrin Roduner, PhD
Katrin Roduner, PhD
Head of Human Resources
 
Simon Messner, PhD
Simon Messner, PhD
Head of Product Management
 
David Fluri, PhD
David Fluri, PhD
Head of Operations
 

Dr. Jens M. Kelm, InSphero AG Co-founder

Dr. Jan Lichtenberg, Chief Executive Officer InSphero AG, Member of the InSphero Management Team

Thomas Pfisterer, Wild Group Management AG

Dr. Jürg Gysi, President of the Board, Switzerland

Former CEO, Promega AG Switzerland. Molecular Biologist with more than 30 years of experience in sales, marketing and management in the biotech industry in Switzerland, Germany and the US.

Beat Schillig, Founder and President IFJ Institute for Young Entrepreneurs

Serial Entrepreneur and Business Angel.

Dr. Thomas Rinderknecht, Senior Partner at Badertscher Rechtsanwälte

Has served on the board of directors of several biotech, pharma and medtech companies, including amongst others Basilea, Speedel AG, Basel, Glycart Biotechnology AG and Ganymed Pharmaceuticals AG. Ph.D. in law from the University of Zurich, admitted to the Bar in Zurich.

Anna Evodokimova, VC Investment Director at Millhouse LLC

Professor Gordon McVie

An international authority on the treatment and research of cancer. Along with Umberto Veronesi, he is the founding editor of ecancermedicalscience, an open access cancer journal from the European Institute of Oncology in Milan.

Dr. Igor Koman

Director of Ariel University’s Institute for Personalized Medicine. Dr. Komen graduated from the Russian Medical University and holds a PhD and DSc in clinical pharmacology.

Charles Qualls, DVM, PhD, DACVP

A toxicology expert who retired as Executive Director of Investigative Toxicology and Pathology at Amgen Inc. Before working at Amgen, Dr. Qualls served as Director of Molecular and Ultrastructural Pathology at GlaxoSmithKline. Dr. Qualls had a distinguished career over two decades in academia prior to moving into the pharmaceutical industry.

Dr. Jean Krutman

Scientific director of the Leibniz Research Institute for Environmental Medicine, Düsseldorf Germany.

Dr. Med. Sci. Frédéric Lévy

Head of Research & Evaluation at Debiopharm International SA and Associate Professor at the Faculty of Biology and Medicine, University of Lausanne with more than 50 peer-reviewed scientific publications. Dr Med Sc, Biochemistry/Immunology and Postdoc at California Institute of Technology.